Evotec SE : Strong Q3 results and confirmation of 2023 guidance reflect resilient business model
>Q3 results ahead of estimates - Evotec’s 9M 2023 results showed strong top-line growth of 13.6% to € 580m, above our estimates of € 572m and the consensus of € 563m. Q3 revenue of € 196m was 4.4% ahead of our and even 10% ahead of consensus estimates. Adj. EBITDA after nine months amounted to € 50.2m vs our estimates of € 48.7m and consensus of € 44.9m. Q3 EBITDA was adjusted for one-off related cyber-attack expenses of € 4.1m and H1 figures were retrospectively adju...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.